An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
Status:
Terminated
Trial end date:
2017-05-24
Target enrollment:
Participant gender:
Summary
This is an exploratory study with the following primary objectives: 1) to establish that
PET/CT of the lung can reliably distinguish healthy, non-asthmatic participants from
participants with severe asthma and an eosinophilic phenotype and 2) to examine the utility
of PET/CT for demonstrating that reslizumab produces a reduction in lung inflammation in
participants with severe asthma and an eosinophilic phenotype .
Phase:
Phase 4
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.